<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21185332</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>135</EndPage><MedlinePgn>127-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2010.12.006</ELocationID><Abstract><AbstractText>Dengue virus (DENV) is a mosquito-borne flavivirus that has strained global healthcare systems throughout tropical and subtropical regions of the world. In addition to plaguing developing nations, it has re-emerged in several developed countries with recent outbreaks in the USA (CDC, 2010), Australia (Hanna et al., 2009), Taiwan (Kuan et al., 2010) and France (La Ruche et al., 2010). DENV infection can cause significant disease, including dengue fever, dengue hemorrhagic fever, dengue shock syndrome, and death. There are no approved vaccines or antiviral therapies to prevent or treat dengue-related illnesses. However, the viral NS2B-NS3 protease complex provides a strategic target for antiviral drug development since NS3 protease activity is required for virus replication. Recently, we reported two compounds with inhibitory activity against the DENV protease in vitro and antiviral activity against dengue 2 (DEN2V) in cell culture (Tomlinson et al., 2009a). Analogs of one of the lead compounds were purchased, tested in protease inhibition assays, and the data evaluated with detailed kinetic analyses. A structure activity relationship (SAR) identified key atomic determinants (i.e. functional groups) important for inhibitory activity. Four "second series" analogs were selected and tested to validate our SAR and structural models. Here, we report improvements to inhibitory activity ranging between &#x223c;2- and 60-fold, resulting in selective low micromolar dengue protease inhibitors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Suzanne M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watowich</LastName><ForeName>Stanley J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI066160-02S1</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI066160-02</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI065396</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007093</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI066160</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C080102">NS2B protein, flavivirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C504449">NS3 protease, dengue virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000873" MajorTopicYN="N">Anthracenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21185332</ArticleId><ArticleId IdType="mid">NIHMS260932</ArticleId><ArticleId IdType="pmc">PMC3026091</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2010.12.006</ArticleId><ArticleId IdType="pii">S0166-3542(10)00825-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, Castro O, Kouri G, Halstead SB, Guzman MG. Dengue hemorrhagic Fever caused by sequential dengue 1&#x2013;3 virus infections over a long time interval: Havana epidemic, 2001&#x2013;2002. Am J Trop Med Hyg. 2006;75:1113&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">17172378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan JF, Fletterick RJ. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology. 1989;171:637&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">2548336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider C, Beer D, Keller TH, Sonntag S, Wen D, Yap L, Yau YH, Shochat SG, Huang D, Zhou T, Caflisch A, Su XC, Ozawa K, Otting G, Vasudevan SG, Lescar J, Lim SP. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem. 2009;395:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682971</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Dengue Fever. 2008</Citation></Reference><Reference><Citation>CDC. Locally acquired Dengue--Key West, Florida, 2009&#x2013;2010. MMWR Morb Mortal Wkly Rep. 2010;59:577&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">20489680</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, Katzenmeier G. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun. 2005;330:1237&#x2013;1246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823576</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A. 1993;90:4171&#x2013;4175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46468</ArticleId><ArticleId IdType="pubmed">8387212</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol. 2006;13:372&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Pethel M, Zhang Y, Lai C. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol. 1991;65:2467&#x2013;2475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240601</ArticleId><ArticleId IdType="pubmed">2016768</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields B, Knipe D, Howley P, Chanock R, Melnick J, Monath T, Roizman B, Strauss S. Field's Virology. Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins; 1996.</Citation></Reference><Reference><Citation>Ganesh VK, Muller N, Judge K, Luan CH, Padmanabhan R, Murthy KH. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem. 2005;13:257&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582469</ArticleId></ArticleIdList></Reference><Reference><Citation>Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18:2714&#x2013;2723.</Citation><ArticleIdList><ArticleId IdType="pubmed">9504803</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna JN, Ritchie SA, Richards AR, Humphreys JL, Montgomery BL, Ehlers GJ, Pyke AT, Taylor CT. Dengue in north Queensland, 2005&#x2013;2008. Commun Dis Intell. 2009;33:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">19877538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ, 3rd, Zalman LS. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47:3907&#x2013;3916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes EC. Virology. Helping the resistance. Science. 2010;328:1243&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">20522766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrobowski YM, Garry RF, Michael SF. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J. 2005;2:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177995</ArticleId><ArticleId IdType="pubmed">15927084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu JT, Wang HC, Chen GW, Shih SR. Antiviral drug discovery targeting to viral proteases. Curr Pharm Des. 2006;12:1301&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorganic &amp; Medicinal Chemistry Letters. 2006;16:3337&#x2013;3340.</Citation><ArticleIdList><ArticleId IdType="pubmed">16621533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan MM, Chang FY, Lin T, Chuang JH, Wu HS. Epidemiological trends and the effect of airport fever screening on prevention of domestic dengue fever outbreaks in Taiwan, 1998&#x2013;2007. Int J Infect Dis. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110484</ArticleId><ArticleId IdType="pubmed">20656647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal Biochem. 1996;237:260&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmic P. DynaFit--a software package for enzymology. Methods Enzymol. 2009;467:247&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">19897096</ArticleId></ArticleIdList></Reference><Reference><Citation>La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay P, Despres P, Lenglet A, Jourdain F, Leparc-Goffart I, Charlet F, Ollier L, Mantey K, Mollet T, Fournier J, Torrents R, Leitmeyer K, Hilairet P, Zeller H, Van Bortel W, Dejour-Salamanca D, Grandadam M, Gastellu-Etchegorry M. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill. 2010;15</Citation><ArticleIdList><ArticleId IdType="pubmed">20929659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14578911</ArticleId></ArticleIdList></Reference><Reference><Citation>Latour DR, Jekle A, Javanbakht H, Henningsen R, Gee P, Lee I, Tran P, Ren S, Kutach AK, Harris SF, Wang SM, Lok SJ, Shaw D, Li J, Heilek G, Klumpp K, Swinney DC, Deval J. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate. Antiviral Res. 2010;87:213&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">20470829</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR, Fairlie DP. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem. 2001;276:45762&#x2013;45771.</Citation><ArticleIdList><ArticleId IdType="pubmed">11581268</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyssen P, De Clercq E, Neyts J. Perspectives for the treatment of infections with Flaviviridae. Clin Microbiol Rev. 2000;13:67&#x2013;82. table of contents.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88934</ArticleId><ArticleId IdType="pubmed">10627492</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP, Harris JL, Vasudevan SG. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem. 2005;280:28766&#x2013;28774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15932883</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks RM, Lu H, Sundaresan R, Toida T, Suzuki A, Imanari T, Hernaiz MJ, Linhardt RJ. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J Med Chem. 2001;44:2178&#x2013;2187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405655</ArticleId></ArticleIdList></Reference><Reference><Citation>Markwardt F, Landmann H, Walsmann P. Comparative studies on the inhibition of trypsin, plasmin, and thrombin by derivatives of benzylamine and benzamidine. Eur J Biochem. 1968;6:502&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">5701967</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003;100:6986&#x2013;6991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens DM, Fauci AS. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA. 2008;299:214&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">18182605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson TC, Padmanabhan R. Identification and biochemical characterization of smallmolecule inhibitors of west nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother. 2008;52:3385&#x2013;3393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533463</ArticleId><ArticleId IdType="pubmed">18606844</ArticleId></ArticleIdList></Reference><Reference><Citation>Patani GA, LaVoie EJ. Bioisosterism: A Rational Approach in Drug Design. Chem Rev. 1996;96:3147&#x2013;3176.</Citation><ArticleIdList><ArticleId IdType="pubmed">11848856</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res. 2009a;82:110&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680748</ArticleId><ArticleId IdType="pubmed">19428601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Malmstrom RD, Watowich SJ. New approaches to structurebased discovery of dengue protease inhibitors. Infect Disord Drug Targets. 2009b;9:327&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">19519486</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Watowich SJ. Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease. Biochemistry. 2008;47:11763&#x2013;11770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648976</ArticleId><ArticleId IdType="pubmed">18855422</ArticleId></ArticleIdList></Reference><Reference><Citation>Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329:174&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">20616270</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998;27:249&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Hsieh Y-C, Lee S-J, Wu S-H, Liao C-L, Tsao C-H, Chao Y-S, Chern J-H, Wu C-P, Yueh A. Novel Dengue Virus-Specific NS2B/NS3 Protease Inhibitor, B 1 P2109, Discovered by a High-Throughput Screening Assay. Antimicrob. Agents Chemother. 2011 doi:10.1128/AAC.00855-10 (published online ahead of print on 11 October 2010)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019636</ArticleId><ArticleId IdType="pubmed">20937790</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JM, Chen YF, Tu YY, Yen KR, Yang YL. Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLos One. 2007;2:e428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855430</ArticleId><ArticleId IdType="pubmed">17502914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox JE, Ma NL, Ehrhardt C, Lim SP, Vasudevan SG, Keller TH. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett. 2006a;16:40&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Patel SJ, Wang WL, Wang G, Chan WL, Rao KR, Alam J, Jeyaraj DA, Ngew X, Patel V, Beer D, Lim SP, Vasudevan SG, Keller TH. Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead. Bioorg Med Chem Lett. 2006b;16:36&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246553</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem. 2000;275:9963&#x2013;9969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>